Drug Trial Radar · NCT00101582
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
Last checked: Nov 20, 2026Latest source record: Sep 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Aug 2005
Primary completion
Sep 2007
Study completion Aug 2016
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Jan 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in the mouth). Mucositis is a common side effect for patients receiving chemotherapy (cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and neck cancer (HNC).
Conditions
- Mucositis
- Solid Tumors
- Stomatitis
- Head and Neck Cancer
- Squamous Cell Carcinoma
Interventions
PlaceboDrug
paliferminDrug
cisplatin chemotherapyDrug
Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m\^2 on Days 1, 22, and 43.
RadiotherapyRadiation
Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Severe (Grade 3 or 4) Oral MucositisTime frame: Up to Week 15
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.